State of Gene Therapy for Monogenic Cardiovascular Diseases.

Bains, Sahej; Giudicessi, John R; Odening, Katja E; Ackerman, Michael J (2024). State of Gene Therapy for Monogenic Cardiovascular Diseases. Mayo Clinic proceedings, 99(4), pp. 610-629. Elsevier 10.1016/j.mayocp.2023.11.003

[img] Text
1-s2.0-S002561962300527X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

Over the past 2 decades, significant efforts have been made to advance gene therapy into clinical practice. Although successful examples exist in other fields, gene therapy for the treatment of monogenic cardiovascular diseases lags behind. In this review, we (1) highlight a brief history of gene therapy, (2) distinguish between gene silencing, gene replacement, and gene editing technologies, (3) discuss vector modalities used in the field with a special focus on adeno-associated viruses, (4) provide examples of gene therapy approaches in cardiomyopathies, channelopathies, and familial hypercholesterolemia, and (5) present current challenges and limitations in the gene therapy field.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Physiology
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Odening, Katja Elisabeth

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0025-6196

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

04 Apr 2024 15:27

Last Modified:

04 Apr 2024 15:37

Publisher DOI:

10.1016/j.mayocp.2023.11.003

PubMed ID:

38569811

BORIS DOI:

10.48350/195652

URI:

https://boris.unibe.ch/id/eprint/195652

Actions (login required)

Edit item Edit item
Provide Feedback